Our team is unique in 1) having demonstrated the feasibility to perform 31P-MRS studies in patients with hypercholesterolemia and 2) having access to individuals that have proven statin myalgia on standardized observed statin-rechallenge. We believe that the data obtained from this study will provide the critical data needed to support application to the NIH for a full-scale clinical trial exploring the relationship between statin use, PCr recovery rate, and ubiquinol therapy.